Q-omics provides the consensus-scored TRIM53CP profile across patient tissues and cancer cell-line models. TRIM53CP expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRIM53CP is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, TRIM53CP RNA expression shows 10,699 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, LUSC, and THYM as cancer lineages where TRIM53CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM53CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM53CP survival associations across molecular data types. TRIM53CP RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM53CP RNA expression–survival associations across cancer types. High TRIM53CP expression shows unfavorable associations in ACC, HNSC, PAAD, LUAD and UVM, but favorable associations in MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRIM53CP RNA expression.
This table summarizes TRIM53CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM53CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM53CP shows higher tumor expression in LUSC. The LUSC box plot shows higher TRIM53CP RNA expression in tumor versus normal tissue (log2 FC = +0.153, t-test p < 0.001).
This table shows molecular features associated with TRIM53CP in patient tissues and cancer cell lines. In patient samples, TRIM53CP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
